法匹拉韦对己糖激酶的抑制作用具有新颖性，与莫努匹韦和 2-脱氧-D-葡萄糖相比，在治疗 COVID-19 方面具有潜在优势。

A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy D glucose in treating COVID-19.

机构信息

Herbal Division, Sava Healthcare Limited, Research Center, Block D1, Plot No. 17/6, MIDC, Chinchwad, Pune, 411019, India.

出版信息

Biotechnol Lett. 2022 Jul;44(7):831-843. doi: 10.1007/s10529-022-03259-6. Epub 2022 May 24.

PURPOSE

In the wake of SARS-CoV-2's global spread, human activities from health to social life to education have been affected. Favipiravir and Molnupiravir exhibited novel hexokinase inhibition and we discuss advantages of this property in their COVID-19 inhibition potential.

METHODS

This paper describes molecular docking data of human hexokinase II with Favipiravir, Cyan 20, Remdesivir, 2DG, and Molnupiravir along with hexokinase inhibition assays.

RESULTS

Favipiravir, an antiviral drug previously cleared for treating the flu and ebola, has shown some promise in early trials to treat COVID-19. We observed potent human hexokinase inhibiting potential of Favipiravir (50%) as against 4% and merely 0.3% hexokinase inhibition with Molnupiravir and 2 Deoxy D glucose at 0.1 mM concentration supported by molecular docking studies.

CONCLUSION

Favipiravir could continue to be part of the COVID-19 treatment regimen due to its resistance to host esterases, hexokinase inhibition potential and proven safety through human trials.

目的

在 SARS-CoV-2 全球传播之后，人类的活动从健康到社交生活再到教育都受到了影响。法匹拉韦和莫努匹韦都表现出了新型的己糖激酶抑制作用，我们讨论了这一特性在其 COVID-19 抑制潜力方面的优势。

方法

本文描述了法匹拉韦、Cyan 20、瑞德西韦、2DG 和莫努匹韦与人己糖激酶 II 的分子对接数据，以及己糖激酶抑制试验。

结果

法匹拉韦是一种先前被批准用于治疗流感和埃博拉的抗病毒药物，在早期治疗 COVID-19 的试验中显示出了一定的前景。我们观察到法匹拉韦对人己糖激酶具有很强的抑制潜力（50%），而莫努匹韦和 2-脱氧-D-葡萄糖在 0.1mM 浓度下对己糖激酶的抑制率分别为 4%和 0.3%，这一结果得到了分子对接研究的支持。